基质金属蛋白酶
基质金属蛋白酶抑制剂
转移
癌症
前列腺癌
癌症研究
医学
肿瘤进展
生物信息学
生物
肿瘤科
内科学
作者
Ali Alaseem,Khalid Alhazzani,Priya Dondapati,Saad Alobid,Anupam Bishayee,Appu Rathinavelu
标识
DOI:10.1016/j.semcancer.2017.11.008
摘要
Matrix metalloproteinases (MMPs) are members of zinc-dependent endopeptidases implicated in a variety of physiological and pathological processes. Over the decades, MMPs have been studied for their role in cancer progression, migration, and metastasis. As a result, accumulated evidence of MMPs incriminating role has made them an attractive therapeutic target. Early generations of broad-spectrum MMP inhibitors exhibited potent inhibitory activities, which subsequently led to clinical trials. Unexpectedly, these trials failed to meet the desired goals, mainly due to the lack of efficacy, poor oral bioavailability, and toxicity. In this review, we discuss the regulatory role of MMPs in cancer progression, current strategies in targeting MMPs for cancer treatment including prodrug design and tumor imaging, and therapeutic value of MMPs as biomarkers in breast, lung, and prostate cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI